Atıf İçin Kopyala
Buti M., Fung S., Gane E., Afdhal N. H., Flisiak R., GÜREL S., ...Daha Fazla
HEPATOLOGY INTERNATIONAL, cilt.9, sa.2, ss.243-250, 2015 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
9
Sayı:
2
-
Basım Tarihi:
2015
-
Doi Numarası:
10.1007/s12072-015-9614-4
-
Dergi Adı:
HEPATOLOGY INTERNATIONAL
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.243-250
-
Anahtar Kelimeler:
Antiviral agent, Chronic hepatitis B, Cirrhosis, Hepatitis B e antigen, Hepatitis B surface antigen, Tenofovir disoproxil, HEPATOCELLULAR-CARCINOMA, ADEFOVIR DIPIVOXIL, FOLLOW-UP, LAMIVUDINE, REGRESSION, THERAPY, DISEASE, LEVEL, RISK
-
Bursa Uludağ Üniversitesi Adresli:
Evet
Özet
Phase 3 clinical studies have shown that long-term treatment with tenofovir disoproxil fumarate (TDF) can suppress hepatitis B viral load and promote significant fibrosis regression and cirrhosis reversal in a majority of treated chronic hepatitis B (CHB) patients. This retrospective analysis investigated the impact of baseline cirrhosis status on virologic, serologic, and histologic outcomes in patients treated with TDF.